Chinese biotech startup Affamed Therapeutics Ltd., funded by CBC Group, has merged with biopharmaceutical company Everinsight Therapeutics Inc., five days after it licensed in a dopamine agonist, KDT-3594, for Parkinson's disease from Japan’s Kissei Pharmaceutical Co. Ltd.